Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

PHASE3CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

October 18, 2017

Primary Completion Date

August 21, 2019

Study Completion Date

April 8, 2021

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

Blinatumomab

"Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).~A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator."

DRUG

Dexamthasone

Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.

Trial Locations (23)

71004

The Second Affiliated Hospital of Xi an Jiaotong University, Xi'an

100191

Peking University Third Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

100853

Chinese People Liberation Army General Hospital, Beijing

102206

Peking University International Hosipital, Beijing

110001

The First Hospital of China Medical University, Shenyang

130021

The First Hospital of Jilin University, Changchun

200040

Huashan Hospital Affiliated to Fudan University, Shanghai

210029

Jiangsu Province Hospital, Nanjing

215006

The First Affiliated Hospital of Soochow University, Suzhou

230001

Anhui Provincial Hospital, Hefei

300020

Institute of Hematology and Blood Diseases Hospital Peking Union Medical College, Tianjin

310003

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

310009

Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou

350001

Fujian Medical University Union Hospital, Fuzhou

410008

Xiangya Hospital Central South University, Changsha

430030

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

450008

Henan Cancer Hospital, Zhengzhou

510080

Guangdong Provincial Peoples Hospital, Guangzhou

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

510120

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

510515

Nanfang Hospital, Southern Medical University, Guangzhou

610041

West China Hospital, Sichuang University, Chengdu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY